PER 1.25% 7.9¢ percheron therapeutics limited

Ann: Positive PDCO opinion and A$20m Placement, page-49

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 720 Posts.
    lightbulb Created with Sketch. 210
    I’ve been reading HC ANP for longer than a month and been a shareholder for much longer than that. The $$$$ shill circle jerk posting here is very obvious. Itsa was talking about commercialisation next year which then become 2023. Well the CR presentation gives the timeline date for marketing approval/commercialisation as end of 2025. I’ve not known too many biotechs that have beaten their schedules and delivered before time. And I’m well aware of the $US 500 mill CR from Sarepta last month. Was just making the point that it is rare for deals in new drugs after a 9 patient phase 2a study and four years until commercialisation assuming they jump over futility analysis and meet endpoints on trial about to commence.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.9¢
Change
-0.001(1.25%)
Mkt cap ! $83.73M
Open High Low Value Volume
8.1¢ 8.2¢ 7.9¢ $153.8K 1.914M

Buyers (Bids)

No. Vol. Price($)
12 927041 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.1¢ 218878 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.